| Literature DB >> 26830934 |
Andreas Roetzer1, Guenter Haller2, John Beyerly3, Christoph B Geier4, Hermann M Wolf5, Corina S Gruener6, Nina Model7, Martha M Eibl8,9.
Abstract
BACKGROUND: Nosocomial infections caused by the bacterial pathogen Staphylococcus aureus can lead to serious complications due to the varying presence of secreted toxins. Comparative studies of genomic information and production rates are needed to assess the pathogenic potential of isolated strains. Genotypic and phenotypic profiling of clinical and colonising isolates of S. aureus was used to characterise the release of exotoxins. Blood isolates were compared with colonisation strains to determine similarities and differences of single strains and clusters.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26830934 PMCID: PMC4736648 DOI: 10.1186/s12866-016-0630-x
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Fig. 1Prevalence of superantigen and superantigen-like genes in blood isolates and colonisation strains. Percentage of distribution of genes identified by PCR was determined, selw was included when sequencing revealed an ATG start codon
Prevalence of superantigen and superantigen-like open reading frames in blood and colonising isolates
| All ( | Blood ( | Colonising ( |
| |
|---|---|---|---|---|
|
| 8 (15.7) | 2 (9.1) | 6 (20.7) | 0.26 |
|
| 1 (1.9) | 0 (0) | 1 (3.4) | nd |
|
| 6 (11.8) | 3 (13.6) | 3 (10.3) | 0.72 |
|
| 1 (1.9) | 0 (0) | 1 (3.4) | nd |
|
| - | - | - | |
|
| 8 (15.7) | 5 (22.7) | 3 (10.3) | 0.23 |
|
| 31 (60.8) | 12 (54.5) | 19 (65.5) | 0.43 |
|
| 3 (5.9) | 1 (4.5) | 2 (6.9) | 0.72 |
|
| 33 (64.7) | 12 (54.5) | 21 (72.4) | 0.19 |
|
| 1 (1.9) | 0 (0) | 1 (3.4) | nd |
|
| - | - | - | |
|
| 6 (11.8) | 3 (13.6) | 3 (10.3) | 0.72 |
|
| 33 (64.7) | 12 (54.5) | 21 (72.4) | 0.19 |
|
| 33 (64.7) | 12 (54.5) | 21 (72.4) | 0.19 |
|
| 33 (64.7) | 12 (54.5) | 21 (72.4) | 0.19 |
|
| 6 (11.8) | 4 (18.2) | 2 (6.9) | 0.22 |
|
| - | - | - | |
|
| 1 (1.9) | 0 (0) | 1 (3.4) | nd |
|
| - | - | - | |
|
| - | - | - | |
|
| 21 (41.2) | 8 (36.4) | 13 (44.8) | 0.54 |
|
| - | - | - | |
|
| 4 (7.8) | 2 (9.1) | 2 (6.9) | 0.77 |
|
| 39 (76.4) | 17 (77.3) | 22 (75.8) | 0.91 |
aNo. of PCR-amplified and sequenced genes, percentages are in parentheses
bPearson’s chi-squared test (χ 2) performed for distribution of in-frame genes (n > 1)
c selu and selu2 combined as selu
d selw with identified ATG as start codon
Results for testing the presence of superantigens, cytolysins and the measurement of protein amounts in hospital-derived isolates
| Isolates | Typing | Superantigens | Cytolysins | α toxin | SEC | TSST | |||
|---|---|---|---|---|---|---|---|---|---|
| ISb |
|
| [μg/ml] | ||||||
|
| Rv53944 | c | t377 | IV |
|
| 25.4 | - | - |
| B7715 | b | t024 | I |
|
| 11.45 | - | - | |
| B3276 | b | t056 | I |
|
| 6.12 | - | - | |
| B3478 | b | t056 | I |
|
| 5.4 | - | - | |
| Rv54213 | c | t648 | I |
|
| 4.83 | - | - | |
| Rv52743 | c | t084 | II |
|
| 1.37 | - | - | |
| Rv54192 | c | t084 | II |
|
| 0.43 | - | - | |
| 771 N-10 | c | t084 | II |
|
| 0.15 | - | - | |
| B7761 | b | t084 | II |
|
| 0.10 | - | - | |
| B5990 | b | t008 | I |
|
| 0.05 | - | - | |
| B50188 | b | t2453 | II |
|
| 0.05 | - | - | |
|
| B958 | b | t790 | I |
|
| 36.13 | 19.71 | - |
| Rv52832 | c | t583 | I |
|
| 7.44 | 5.77 | - | |
| Rv51398 | c | t230 | I |
|
| 6.05 | 11.12 | - | |
| 876 N-10 | c | t333 | I |
|
| 2.72 | 1.95 | - | |
| B1721 | b | t015 | I |
|
| 2.75 | 6.93 | - | |
| B3427 | b | t015 | I |
|
| 1.75 | 5.79 | - | |
|
| B2284 | b | t067 | II |
|
| 0.99 | - | 2.83 |
| B1848 | b | t021 | III |
|
| ≤0.01 | - | 3.71 | |
| B1793 | b | t021 | III |
|
| ≤0.01 | - | 3.24 | |
| 840 N-10 | c | t342 | III |
|
| ≤0.01 | - | 0.5 | |
| B34571 | b | t342 | III |
|
| ≤0.01 | - | 0.85 | |
| B11019 | b | t15407c | III |
|
| ≤0.01 | - | 2.66 | |
| Rv52959 | c | t012 | III |
|
| ≤0.01 | - | 0.06 | |
| Rv54054 | c | t3805 | III |
|
| ≤0.01 | - | 0.01 | |
|
| Rv53955 | c | t246 | IV |
|
| 6.58 | - | - |
| Rv54216 | c | t246 | IV |
|
| 2.88 | - | - | |
| 784 N-10 | c | t065 | I |
|
| 8.26 | - | - | |
| Rv51334 | c | t13078 | I |
|
| 11.64 | - | - | |
| Rv51410 | c | t617 | III |
|
| ≤0.01 | - | - | |
| Rv51412 | c | t11980 | III |
|
| ≤0.01 | - | - | |
| Rv52825I | c | t005 | I |
|
| 0.02 | - | - | |
| Rv52825II | c | t350 | I |
|
| 3.99 | - | - | |
| B7709 | b | t3232 | I |
|
| 1.85 | - | - | |
| B8186 | b | t553 | I |
|
| 4.55 | - | - | |
| Rv54035 | c | t284 | IV |
|
| 2.87 | - | - | |
| B16586 | b | t4401 | III |
|
| ≤0.01 | - | - | |
| B1455 | b | t071 | II |
|
| 1.01 | - | - | |
| 803 N-10 | c | t1441 | IV |
|
| 28.23 | - | - | |
|
| Rv54209 | c | t548 | II |
|
| 0.29 | - | - |
| 869 N-10 | c | t002 | II |
|
| 2.01 | - | - | |
| B69108 | b | t091 | I |
|
| 1.73 | - | - | |
| B24743 | b | t091 | I |
|
| 0.69 | - | - | |
| B3597 | b | t091 | I |
|
| 1.52 | - | - | |
| Rv54009 | c | t433 | III |
|
| 1.58 | - | - | |
| Rv54010 | c | t433 | III |
|
| 1.45 | - | - | |
| Rv52745 | c | t3802 | I |
|
| 2.44 | - | - | |
| B3155 | b | t3308 | I |
|
| 2.16 | - | - | |
| 767 N-10 | c | t008 | I |
|
| 3.80 | - | - | |
| Rv51379 | c | t6873 | II |
|
| 0.31 | - | - | |
| 638 N-10 | c | t878 | III |
|
| 7.34 | - | - | |
aexcept selw and selx
bIsolation Site including (b) blood isolates and (c) colonising strains
cnew, unique repeat pattern 04-54-31-12-16-34-16-12-25
dno selu
edue to the absence of the atg start codon designated as pseudogene
fframeshift nonsense mutation in selx (I11)
gnonsense mutation in hla (Q113)
hframeshift nonsense mutation in hla (M317) plus a different C-terminus E315K E316K
Characterisation of clonal complexes and comparison of alpha toxin production rates
| Clonal complex | ST (n) |
|
| Superantigensb | Production (m/sd)d α toxin |
|---|---|---|---|---|---|
| CC5 | ST5 (3) | t071, t548, t002 | II (3) |
| 1.1 (+/−0.7) |
| ST1457 (1) | t067 | II |
| ||
| CC6 | ST6 (1) | t3802 | I |
| |
| ST7 | ST7 (3) | t091 (3) | I (3) |
| 1.32 (+/−0.55) |
| CC8 | ST8 (4) | t3308, t024, t008, t648 | I (5) |
| 8.78 (+/−10.23) |
| ST3275 (1)a | t008 |
| |||
| ST630 (1) | t377 | IV |
| ||
| CC10 | ST10 (1) | t6873 | II |
| |
| CC15 | ST15 (2) | t2453, t084 | II (5) |
| 0.42 (+/−0.55) |
| ST582 (3) | t084 (3) |
| |||
| CC22 | ST22 (3) | t790, t13078, t005 | I (3) |
| 15.93 (+/−18.43) |
| CC25 | ST25 (1) | t3232 | I |
| |
| CC30 | ST30 (10) | t433 (2), t4401, t11980, t617, t012, t021 (2), t342 (2) | III (10) |
| ≤0.01 |
| ST34 (2) | t3805, t15407 | III (2) |
| ||
| CC45 | ST45 (8) | t015 (2), t333, t230, t583, t065, t350, t553 | I (8) |
| 4.69 (+/−2.36) |
| CC50 | ST50 (2) | t246 (2) | IV (2) |
| |
| CC51 | ST121 (2) | t284, t1441 | IV (2) |
| |
| CC101 | ST101 (2) | t056 (2) | I (2) |
| |
| CC779 | ST779 (1) | t878 | III |
|
aStrain 767 N-10 displayed a different allele of aroE, being a new single locus variant of ST8
bAll superantigen genes were included with the exception of pseudogenes
cSuperantigen-like gene selx including frameshift nonsense mutation (I11)
dMean (m) and standard deviation (sd) of production rates were determined of CC groups comprising one or more STs (number of strains n ≥ 3)
Comparison of protein amounts in spa typing clusters with identical superantigen and alpha toxin gene patterns of hospital-derived isolates
| Typing | α toxin | SEC | TSST1 | ||||
|---|---|---|---|---|---|---|---|
| IS |
|
| CC | [μg/ml] | |||
| B3276 | b | t056 | I | 101 | 6.12 | - | - |
| B3478 | b | t056 | I | 5.4 | - | - | |
| Rv52743 | c | t084 | II | 15 | 1.37 | - | - |
| Rv54192 | c | t084 | II | 0.43 | - | - | |
| 771 N-10 | c | t084 | II | 0.15 | - | - | |
| B7761 | b | t084 | II | 0.10 | - | - | |
| B1721 | b | t015 | I | 45 | 2.75 | 6.93 | - |
| B3427 | b | t015 | I | 1.75 | 5.79 | - | |
| B1848 | b | t021 | III | 30 | ≤0.01 | - | 3.71 |
| B1793 | b | t021 | III | ≤0.01 | - | 3.24 | |
| 840 N-10 | c | t342 | III | 30 | ≤0.01 | - | 0.5 |
| B34571 | b | t342 | III | ≤0.01 | - | 0.85 | |
| Rv53955 | c | t246 | IV | 50 | 6.58 | - | - |
| Rv54216 | c | t246 | IV | 2.88 | - | - | |
| B69108 | b | t091 | I | ST7 | 1.73 | - | - |
| B24743 | b | t091 | I | 0.69 | - | - | |
| B3597 | b | t091 | I | 1.52 | - | - | |
| Rv54009 | c | t433 | III | 30 | 1.58 | - | - |
| Rv54010 | c | t433 | III | 1.45 | - | - | |
Fig. 2Hemolysis of erythrocytes through supernatants from S. aureus depends on alpha toxin and gamma toxin. a To measure percentage of hemolysis, cells were grown to stationary phase, and sterile-filtered supernatants were diluted 1:50 in 1X PBS. Absolute hemolysis was defined as the optical density of freed heme upon the addition of the natural glycoside saponin (from Quillaja saponaria) and was set at 100%. Each run of hemolysis was accompanied by parallel measurement of saponin as positive control and 1X PBS as negative control. Percentages were calculated from mean values out of three independent experiments. Groups i) to iii) are defined in the text. Recombinant wild type alpha toxin and recombinant wild type gamma toxin were diluted in 1X PBS to receive 100 ng, 10 ng, and 1 ng per well. For neutralisation, 100 ng of toxin was incubated with or without 50-fold diluted antisera (AS) in parallel for 1 h at 37 °C. b Western blot analysis of HLG1 protein levels in the supernatants of tst-positive isolates. 20 μl were taken from each supernatant (sn) and loaded undiluted. 0.1 μg/μl of recombinant wild type HLG1 was used as positive control (lane 1, grey arrow). Broad range standard (Biorad) was added to identify correct bands (lane 2). Upon blotting, membrane was cut to avoid extensive background. c Neutralisation of hemolysis of erythrocytes through antisera was assessed. To verify specificity, antiserum against alpha toxin or gamma toxin was used as control for the opposite hemolysin (100 ng per well). Antisera were applied in a final 50-fold dilution and incubated for 1 h at 37 °C. Hemolysis and percentage calculation (here for neutralisation of hemolysis) was done as described in (a)
Analysis of hemolytic performance of hemolysins upon neutralisation in hospital-derived isolates
| Isolates | Cytolysins | >90 % Inhibition of hemolysis | |||
|---|---|---|---|---|---|
| α toxin ASc | γ toxin ASc | α/γ toxin ASc | |||
|
| Rv53944 |
| 1:50/1:200 | ||
| B7715 |
| 1:100/1:200 | |||
| B3478 |
| 1:400/1:400 | |||
| Rv54213 |
| 1:400/1:200 | |||
| Rv54192 |
| 1:400/1:400 | |||
| B3276 |
| 1:400 | |||
| Rv52743 |
| 1:400 | |||
| B50188 |
| 1:400 | |||
| 771 N-10 |
| 1:400 | |||
| B5990 |
| 1:400 | |||
| B7761 |
| 1:400 | |||
|
| B958 |
| 1:50/ 1:400 | ||
| Rv52832 |
| 1:400/1:200 | |||
| Rv51398 |
| 1:400/1:200 | |||
| B1721 |
| 1:400/1:400 | |||
| 876 N-10 |
| 1:400/1:400 | |||
| B3427 |
| 1:400/1:400 | |||
|
| B2284 |
| 1:400 | ||
| B11019 |
| 1:200 | |||
| 840 N-10 |
| 1:400 | |||
| B34571 |
| 1:200 | |||
| B1848 |
| 1:200 | |||
| B1793 |
| 1:200 | |||
| Rv52959 |
| - | - | - | |
| Rv54054 |
| - | - | - | |
aexcept selw and selx
bnonsense mutation in hla (Q113)
c AS antiserum